HBK INVESTMENTS L P
Institutional investor · Portfolio as of Q3 2019
Top Holdings613 positions
CELGENE CORP | 15.8M | $1.6B | 20.1% | — | — | 1 qtr | New 98 |
WELLCARE HEALTH PLANS INC | 2.4M | $633.8M | 8.1% | — | — | 2 qtrssince 2019-Q2 | Unchanged 0 |
| 2.2M | $527.8M | 6.7% | — | — | — | Decreased — | |
CYPRESS SEMICONDUCTOR CORP | 18M | $420.1M | 5.4% | — | — | 3 qtrssince 2019-Q1 | Increased 98 |
| 213M | $217M | 2.8% | — | — | 2 qtrssince 2019-Q2 | Increased 63 | |
| 118M | $115.4M | 1.5% | — | — | 3 qtrssince 2019-Q1 | Increased 49 | |
| 15,000 | $106.5M | 1.4% | — | — | — | New — | |
| 15,000 | $106.5M | 1.4% | — | — | — | New — | |
| 3.5M | $105.6M | 1.4% | — | — | — | Increased — | |
PETROLEO BRASILEIRO S A | 7.9M | $103.5M | 1.3% | $3.97 | +469.71% | 3 qtrssince 2019-Q1 | Unchanged 0 |
| 500,000 | $94.4M | 1.2% | — | — | — | Decreased — | |
| 52.9M | $90M | 1.2% | — | — | 1 qtr | New 68 | |
| 3M | $70.9M | 0.9% | — | — | — | New — | |
SINA CORP | 1.6M | $63.8M | 0.8% | — | — | 3 qtrssince 2019-Q1 | Increased 47 |
| 50.3M | $50.8M | 0.6% | — | — | 3 qtrssince 2019-Q1 | Decreased 0 | |
TAKEDA PHARMACEUTICAL CO LTD | 2.6M | $45.4M | 0.6% | $19.07 | +1.99% | 3 qtrssince 2019-Q1 | Unchanged 0 |
LIBERTY MEDIA COR-SIRIUSXM A | 1M | $42M | 0.5% | — | — | 3 qtrssince 2019-Q1 | Increased 44 |
| 2.3M | $37.6M | 0.5% | — | — | — | Increased — | |
| 37.6M | $37.2M | 0.5% | — | — | 3 qtrssince 2019-Q1 | Unchanged 0 | |
FS KKR CAPITAL CORP | 6.3M | $36.7M | 0.5% | $8.20 | +2.63% | 3 qtrssince 2019-Q1 | Decreased 0 |
HBK INVESTMENTS L P manages $7.8B across 613 positions as of Q3 2019. Top holdings: CELG (20.1%), WCG (8.1%), TESLA INC puts (6.7%). Fund DNA: Momentum Trader. HoldingsIntel Score: 3/5.0.
Active quarter - 98 new positions, 151 exits, 63 increased. Top move: CELG (NEW, conviction 98). Portfolio: $7.8B across 613 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR